Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905095 | 0.83 | PKM (0.50) | PTGDR2TDP1TSHRPOLBCTDSP1 | |
| SCHEMBL1615073 | 0.82 | PKM (0.70) | PTGDR2TDP1TSHRPOLBCTDSP1 | |
| SCHEMBL5833932 | 0.82 | TDP1 (0.50) | PTGDR2TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL3044855 | 0.81 | PTGDR2 (0.79) | PTGDR2TDP1TSHRPOLBCTDSP1 | |
| SCHEMBL3203774 | 0.79 | PTGDR2 (0.64) | PTGDR2TDP1TSHRPOLBCTDSP1 | |
| SCHEMBL3203787 | 0.79 | TDP1 (0.70) | PTGDR2TDP1TSHRPOLBCTDSP1 | |
| SCHEMBL1332580 | 0.79 | TDP1 (0.70) | PTGDR2TDP1TSHRPTGDR | |
| SCHEMBL1028925 | 0.79 | PTGDR2 (0.60) | PTGDR2TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL3198632 | 0.79 | PTGDR2 (0.67) | PTGDR2TDP1TSHRPOLBCTDSP1 | |
| SCHEMBL4625499 | 0.79 | PTGDR2 (0.79) | PTGDR2TDP1TSHRPOLBCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| EP-2396295-A1 | PHENOXY ACETIC ACID DERIVATIVES | Merck Serono S.A. (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | PTGDR2 51/4885TDP1 4632/4885TSHR 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.